Nimenrix was approved by the EC to treat invasive meningococcal disease. | Courtesy of Shutterstock
+ Regulatory
Jeff Gantt | Dec 24, 2016

European Commission approves Nimenrix for meningococcal disease

Pfizer recently announced that an expanded indication for Nimenrix has been approved by the European Commission (EC).

Nimenrix was granted expanded indication by EC for active immunization against invasive meningococcal disease (IMD) linked to Neisseria meningitidis serogroups A, C, W-135 and Y (MenACWY) found in infants.

The disease can be found in infants as young as six weeks old.

“With this approval, Nimenrix now has the broadest age indication of any conjugate vaccine in Europe against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y, to help protect people as young as six weeks of age,” Pfizer Chief Medical and Scientific Affairs Officer Luis Jodar said. “At Pfizer, our expertise in bringing new indications and therapies to people in need helps enable us to continually improve and expand our portfolio of potentially life-saving vaccines.”

With EC approval, Nimenrix becomes the first and currently only MenACWY conjugate vaccine available in the European Union (EU) that can be used on infants beginning at six weeks of age and having no upper age limit.

Approval came due to the results of a phase 3 study that evaluated the immunogenicity and safety of Nimenrix.

Organizations in this story

+ Pfizer

More News